Top Stories
The names of more potential nominees for FDA chief have emerged, plus complete response letters for Sobi and Lantheus.
An AI-driven MRI imaging analysis found that all three patients achieved muscle mass gains six months after treatment.
The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the study supporting approval of Tavneos for ANCA-associated vasculitis was "conducted in breach of good clinical practice principles."
The probe focuses on a campaign primarily targeted to healthcare professionals in Germany and France, and disparaging statements about CSL Seqirus' influenza vaccine Fluad.
Ionis granted Recordati exclusive ex-US rights to zilganersen, an investigational RNA-targeted treatment for the rare neurological condition Alexander disease.
Conference News
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Insilico Medicine caps monumental week at BIO 2026: Secures landmark $2.5B partnership and dominates thought leadership | EurekAlert!CAMBRIDGE, MA — June 26, 2026 — Insilico Medicine (“Insilico”), a c...
FRONTIER4 data on investigational denecimig: Exploring efficacy and safety across dosing frequencies for pediatric, adolescent, and adult haemophilia A patients, with or without inhibitorsExplorer10 d...
Two analyses of updated three-year follow-up data from the pivotal Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in BRAF-altered pediatric low-grade glioma will be featured in separate oral present...
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 CongressSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a la...
